We feel now is a pretty good time to analyse Avadel Pharmaceuticals plc's (NASDAQ:AVDL) business as it appears the company may be on the cusp of a considerable accomplishment. Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The US$742m market-cap company announced a latest loss of US$49m on 31 December 2024 for its most recent financial year result. Many investors are wondering about the rate at which Avadel Pharmaceuticals will turn a profit, with the big question being “when will the company breakeven?” We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Avadel Pharmaceuticals is bordering on breakeven, according to the 10 American Pharmaceuticals analysts. They expect the company to post a final loss in 2024, before turning a profit of US$15m in 2025. Therefore, the company is expected to breakeven roughly a year from now or less! We calculated the rate at which the company must grow to meet the consensus forecasts predicting breakeven within 12 months. It turns out an average annual growth rate of 48% is expected, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.NasdaqGM:AVDL Earnings Per Share Growth April 14th 2025

Given this is a high-level overview, we won’t go into details of Avadel Pharmaceuticals' upcoming projects, however, keep in mind that by and large pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

See our latest analysis for Avadel Pharmaceuticals

One thing we would like to bring into light with Avadel Pharmaceuticals is its relatively high level of debt. Typically, debt shouldn’t exceed 40% of your equity, which in Avadel Pharmaceuticals' case is 50%. Note that a higher debt obligation increases the risk in investing in the loss-making company.

Next Steps:

There are key fundamentals of Avadel Pharmaceuticals which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Avadel Pharmaceuticals, take a look at Avadel Pharmaceuticals' company page on Simply Wall St. We've also compiled a list of relevant factors you should further examine:

Story Continues

Valuation: What is Avadel Pharmaceuticals worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Avadel Pharmaceuticals is currently mispriced by the market. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Avadel Pharmaceuticals’s board and the CEO’s background. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments